FDA Dismisses Advisory Committee Meeting for Corcept Therapeutics (CORT) New Drug Application for CORLUX
Up)
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has been advised by the FDA that no advisory committee meeting will be scheduled in connection with its review of the New Drug Application for CORLUX for the treatment of the manifestations of Cushing's Syndrome.
This decision does not alter the Prescription Drug User Fee Act goal date for completion of review which remains February 17, 2012.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
This decision does not alter the Prescription Drug User Fee Act goal date for completion of review which remains February 17, 2012.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Corcept Therapeutics (CORT) Files 4.2M Common Shelf for Shareholders
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Bayer, Onyx Pharma (ONXX) Say Nexavar Missed Primary Endpoint in Phase 3
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
